Home
URGN
URGN News

Latest UroGen Pharma Ltd. (URGN) News on August 23, 2025

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy

Insider Monkey

2 months ago

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy

MT Newswires

2 months ago

HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target

High Growth Tech Stocks in US for June 2025

Simply Wall St.

2 months ago

High Growth Tech Stocks in US for June 2025

FDA approves UroGen’s Zusduri for non-muscle invasive bladder cancer

TipRanks

2 months ago

FDA approves UroGen’s Zusduri for non-muscle invasive bladder cancer

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

BioPharma Dive

2 months ago

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

MT Newswires

2 months ago

Scotiabank Raises UroGen Pharma Price Target to $47 From $23, Maintains Sector Outperform Rating

U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Business Wire

2 months ago

U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

MT Newswires

2 months ago

Urogen Pharma's Bladder Cancer Drug Receives US FDA Approval

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Oppenheimer Adjusts UroGen Pharma Price Target to $10 From $36, Maintains Outperform Rating

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Business Wire

3 months ago

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Business Wire

3 months ago

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

GOBankingRates

3 months ago

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

3 International Vacations That Are Cheaper Than an iPhone

GOBankingRates

3 months ago

3 International Vacations That Are Cheaper Than an iPhone

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

GOBankingRates

3 months ago

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

This week in Trumponomics: Too bad TACO isn’t true

Yahoo Finance

3 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

The Guardian

3 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Yahoo Finance Video

3 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Benzinga

3 months ago

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Reuters

3 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Business Wire

3 months ago

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

MT Newswires

3 months ago

UroGen Pharma Shares Fall After HC Wainwright Downgrade

MT Newswires

3 months ago

HC Wainwright Downgrades UroGen Pharma to Neutral From Buy

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

BioPharma Dive

3 months ago

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

MT Newswires

3 months ago

Top Midday Decliners

MT Newswires

3 months ago

UroGen Pharma Shares Fall After US FDA Committee Vote on Bladder Cancer Drug

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Business Wire

3 months ago

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Biotech Alert: Searches spiking for these stocks today

TipRanks

3 months ago

Biotech Alert: Searches spiking for these stocks today

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price

Simply Wall St.

3 months ago

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...

GuruFocus.com

3 months ago

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...

Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates

Zacks

3 months ago

Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update

Business Wire

3 months ago

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Business Wire

4 months ago

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Business Wire

4 months ago

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?

Zacks

4 months ago

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?

MT Newswires

4 months ago

Top Premarket Gainers

MT Newswires

4 months ago

UroGen Pharma Reports Nearly 4-Year Response for Urothelial Cancer Therapy -- Shares Up Pre-Bell

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

Business Wire

4 months ago

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

Business Wire

4 months ago

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

Business Wire

4 months ago

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Business Wire

4 months ago

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

Business Wire

4 months ago

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

MT Newswires

4 months ago

Scotiabank Initiates UroGen Pharma at Sector Outperform With $23 Price Target

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

Business Wire

4 months ago

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

High Growth Tech Stocks In The US To Watch April 2025

Simply Wall St.

4 months ago

High Growth Tech Stocks In The US To Watch April 2025

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...

GuruFocus.com

5 months ago

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

Zacks

5 months ago

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

Business Wire

5 months ago

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

Exploring High Growth Tech Stocks in the US Market

Simply Wall St.

6 months ago

Exploring High Growth Tech Stocks in the US Market

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

Business Wire

6 months ago

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?

Insider Monkey

6 months ago

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

Business Wire

6 months ago

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen acquires IconOVir’s oncolytic virus assets

Pharmaceutical Technology

6 months ago

UroGen acquires IconOVir’s oncolytic virus assets

MT Newswires

6 months ago

UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

Business Wire

6 months ago

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

Business Wire

6 months ago

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

Business Wire

6 months ago

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

UroGen Pharma to Present at Upcoming Investor Conferences

Business Wire

7 months ago

UroGen Pharma to Present at Upcoming Investor Conferences

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

Business Wire

7 months ago

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

Business Wire

7 months ago

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)

Simply Wall St.

8 months ago

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Business Wire

9 months ago

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

Business Wire

9 months ago

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade

Zacks

9 months ago

Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

Business Wire

9 months ago

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment

Clinical Trials Arena

9 months ago

UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment

MT Newswires

9 months ago

UroGen Pharma Says Jelmyto Chemoablation Shows Long-Term Duration of Response in Urothelial Cancer Patients

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Business Wire

9 months ago

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target

Simply Wall St.

9 months ago

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

GuruFocus.com

10 months ago

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

Business Wire

10 months ago

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

Business Wire

10 months ago

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

Business Wire

10 months ago

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Business Wire

10 months ago

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years

Simply Wall St.

10 months ago

Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years

FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment

Pharmaceutical Technology

10 months ago

FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment

MT Newswires

10 months ago

UroGen Pharma Says US FDA Accepts New Drug Application for Bladder Cancer Treatment

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Business Wire

10 months ago

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com

10 months ago

UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

MT Newswires

10 months ago

UroGen Pharma Appoints Chris Degnan as CFO

UroGen Appoints Chris Degnan as Chief Financial Officer

Business Wire

10 months ago

UroGen Appoints Chris Degnan as Chief Financial Officer

UroGen begins subject dosing in Phase III bladder cancer drug trial

Clinical Trials Arena

a year ago

UroGen begins subject dosing in Phase III bladder cancer drug trial

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Business Wire

a year ago

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now

Insider Monkey

a year ago

UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now

UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock

Insider Monkey

a year ago

UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock

MT Newswires

a year ago

UroGen Pharma Gets Notice of Allowance in US for Patent Related to Cancer Treatment Methods

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Business Wire

a year ago

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Present at Upcoming Investor Conferences

Business Wire

a year ago

UroGen Pharma to Present at Upcoming Investor Conferences

MT Newswires

a year ago

Guggenheim Initiates UroGen Pharma at Buy With $40 Price Target

UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88

Simply Wall St.

a year ago

UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88

MT Newswires

a year ago

UroGen Pharma Submits New Drug Application for Investigational Bladder Cancer Drug

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Business Wire

a year ago

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates

Zacks

a year ago

Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

Business Wire

a year ago

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Business Wire

a year ago

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Share on Social Networks: